Recuperative effect of metformin loaded polydopamine nanoformulation promoting EZH2 mediated proteasomal degradation of phospho-α-synuclein in Parkinson’s disease model-Reference-Cited by-同舟云学术

Recuperative effect of metformin loaded polydopamine nanoformulation promoting EZH2 mediated proteasomal degradation of phospho-α-synuclein in Parkinson’s disease model

Published:2020-02 Issue: Volume:24 Page:102088
ISSN:1549-9634
Container-title:Nanomedicine: Nanotechnology, Biology and Medicine
language:en
Short-container-title:Nanomedicine: Nanotechnology, Biology and Medicine

Author:

Sardoiwala Mohammed Nadim,Srivastava Anup K.,Kaundal Babita,Karmakar Surajit,Choudhury Subhasree Roy

Funder

Science and Engineering Research Board

Department of Biotechnology

Publisher

Elsevier BV

Subject

Pharmaceutical Science,General Materials Science,Biomedical Engineering,Molecular Medicine,Medicine (miscellaneous),Bioengineering

Reference55 articles.

1. Epidemiology of Parkinson's disease and movement disorders in India: problems and possibilities;Muthane;The Journal of the Association of Physicians of India.,2007

2. Parkinson disease;Poewe;Nature Reviews Disease Primers.,2017

3. Novel antibodies to phosphorylated alpha-synuclein serine 129 and NFL serine 473 demonstrate the close molecular homology of these epitopes;Rutherford;Acta neuropathologica communications.,2016

4. Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain;Devi;The Journal of biological chemistry.,2008

5. Advances in epigenetics and epigenomics for neurodegenerative diseases;Qureshi;Curr Neurol Neurosci Rep.,2011

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting the epigenome with advanced delivery strategies for epigenetic modulators;Bioengineering & Translational Medicine;2024-08-17

2. Immunomodulator-Derived Nanoparticles Induce Neuroprotection and Regulatory T Cell Action to Alleviate Parkinsonism;ACS Applied Materials & Interfaces;2024-07-17

3. Nanotechnology-Driven Therapeutic Innovations in Neurodegenerative Disorders: A Focus on Alzheimer’s and Parkinson’s Disease;Future Pharmacology;2024-04-30

4. Hytrin Nanoformulation Reduces Nitrated Synucleinopathy Through Chaperon-Mediated Autophagy;ACS Applied Nano Materials;2024-04-15

5. Advances in the study of polydopamine nanotechnology in central nervous system disorders;Frontiers in Materials;2024-04-12